Liposomal irinotecan for children with rhabdomyosarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new way to treat rhabdomyosarcoma using a targeted drug (liposomal irinotecan) based on the tumor's genetic makeup and risk group. It aims to improve outcomes for children and young adults with intermediate or high-risk disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are under 22 years old.
- You have been diagnosed with rhabdomyosarcoma, a type of muscle cancer, of any subtype.
- You have a risk classification (low, intermediate, or high) determined by your doctor based on tumor features and spread.
- You have not had chemotherapy or radiation for this cancer before (except in emergencies).
- Your kidney, liver, and bone marrow function are within acceptable ranges, based on blood tests.
- If you have a urinary tract blockage from the tumor, it must be relieved before starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different chemotherapy schedules for children and young adults with intermediate-risk rhabdomyosarcoma (a type of muscle cancer). One group gets a higher dose of chemotherapy over a shorter period, while the other gets a lower dose plus maintenance therapy for a longer time. The goal is to see which approach works better.
This study tests different treatment approaches for rhabdomyosarcoma (RMS) in children and adults, including newly diagnosed high-risk cases, people needing radiotherapy, and people whose RMS has returned. It’s designed to find safer dosing and more effective therapy while checking whether participants can proceed based on health and timing requirements.
This trial tests whether a cancer immunotherapy medicine (atezolizumab) given together with chemotherapy can shrink or control solid tumors that have come back or did not respond to prior treatment. It focuses on children and young adults, including a special subgroup for rhabdomyosarcoma.
This study tests a combination of two drugs, MM-398 and cyclophosphamide, for children and young adults whose cancer has come back or not responded to earlier treatment. The goal is to find the best dose and see how well it works against certain tumor types.
This trial tests a new drug, silmitasertib, combined with standard chemotherapy for children and young adults with cancers that have come back or not responded to treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
This trial tests a new combination treatment for intermediate-to-high risk rhabdomyosarcoma, a type of muscle cancer. It combines a standard chemotherapy regimen (VAC) with a vitamin A derivative called all-trans retinoic acid, which may help the chemo work better.
Hear when a new Rhabdomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.